超重治療市場：依產品類型、最終用戶、地區 - 全球產業分析、規模、佔有率、成長、趨勢、預測，2024-2031 年

對全球超重治療市場的全面分析提供了對其成長動力、課題和新興趨勢的見解。這份詳細的報告提供了獨特的數據和統計數據來預測 2024 年至 2031 年的市場軌跡。

重要見解

• 市場規模（2024年）：412億美元
• 預計市值（2031 年）：741 億美元
• 全球市場成長率（2024-2031年複合年增長率）：7.8%

超重治療市場 – 研究範圍

超重治療市場解決了全世界對肥胖和超重狀況日益關注的問題，提供各種治療介入、生活方式改變和外科手術來改善體重管理和整體健康。隨著久坐生活方式、不健康飲食習慣和代謝異常的增加，肥胖已成為全球流行病，增加了對有效治療解決方案的需求。該市場包括藥品、醫療器材、外科手術以及旨在體重管理和預防肥胖的生活方式乾預措施。

市場成長動力：

肥胖和超重的盛行率日益增加，以及人們對超重相關健康風險的認識不斷增強，推動了全球對超重治療解決方案的需求。不良飲食、缺乏運動和壓力等生活方式習慣導致肥胖流行，從而促使體重管理療法和乾預措施的市場不斷增長。此外，旨在預防和治療肥胖的政府措施、公共衛生運動和報銷政策進一步刺激了市場成長。

市場限制：

儘管人們對超重治療解決方案的認識和需求不斷增加，但一些課題阻礙了市場的成長。其中包括服務欠缺地區獲得醫療保健服務的機會有限、肥胖盛行率的社會經濟差異以及採取健康生活方式的文化障礙。此外，圍繞肥胖的恥辱以及認為體重管理是美容問題而不是醫療問題的觀念給醫療保健提供者和政策制定者有效解決肥胖流行問題帶來了課題。

市場機會：

超重治療不斷發展的格局為醫療保健、製藥、營養和健身等多個領域的創新和合作提供了機會。醫療技術的進步將注意力集中在個人化的體重管理方法上，將遺傳、代謝和行為因素納入治療策略。此外，數位健康解決方案、穿戴式裝置和遠距醫療平台的整合正在增強肥胖管理計畫的可近性和參與度，為市場擴張創造新的機會。

本報告解決的關鍵問題

• 推動超重治療市場成長的關鍵因素是什麼？
• 科技進步如何形塑肥胖管理和減重幹預措施？
• 阻礙市場成長的主要課題是什麼？
• 哪些地區的超重治療市場預計將顯著成長？
• 誰是主要市場利害關係人？

競爭資訊與經營策略：

超重治療市場的領導者專注於創新、研究和策略聯盟，以應對肥胖管理的複雜課題。製藥公司將投資開發與肥胖相關的代謝紊亂的新療法，醫療設備製造商將引進用於微創減肥手術的先進設備。此外，醫療保健提供者與健康組織、營養師和健身專家合作，提供適合個人需求的全面體重管理計劃。

主要公司簡介：

• Novo Nordisk A/S
• Roche Holding AG
• GlaxoSmithKline plc
• Medtronic plc
• Johnson & Johnson Services, Inc.
• Allergan plc
• Abbott Laboratories
• Pfizer Inc.
• Amgen Inc.
• Merck & Co., Inc.

超重治療市場研究細分：

依治療分類的超重治療市場

• 藥物治療
• 安非他酮和納曲酮
• 奧利司他
• 芬特明和托□酯
• 利拉魯□
• 其他
• 補充
• 醫療器材/植入物
• 胃氣球
• 胃束帶
• 裝訂設備

超重治療市場：依分銷管道分類

• 設施銷售
• 醫院
• 專科診所
• 門診手術中心
• 零售銷售
• 零售藥店
• 藥店
• 超市/大賣場
• 保健美容店
• 網上銷售

依地區劃分的超重治療市場

• 北美
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東/非洲

目錄

第一章內容提要

第二章市場概況

• 市場範圍/分類
• 市場定義/範圍/限制
• 包含/排除

第 3 章主要市場趨勢

• 影響市場的主要趨勢
• 創新/發展趨勢

第 4 章關鍵成功因素

• 產品採用分析
• 各國肥胖率
• 超重治療藥物管線分析
• 肥胖藥物戒斷分析
• 撤回超重治療藥物和醫療器材、暫停臨床試驗
• 監管場景
• 廠商主要促銷策略
• 波特的分析
• PESTEL 分析

第 5 章 COVID-19 危機分析

• 目前的 COVID-19 統計數據和未來潛在的影響
• 當前 GDP 預測與預期影響
• 目前經濟預測 與 2008 年相比的經濟分析
• COVID-19 與影響分析
  • 收入：依治療分類
  • 收入：依分銷管道劃分
  • 收入：依國家分類

第六章市場背景

• 宏觀經濟因素
• 預測變量 - 相關性和影響
• 市場動態

第七章 全球超重治療市場需求分析（2019-2023）及預測（2024-2031）

• 過往市值分析（2019-2023）
• 目前和未來的市值預測（2024-2031）
  • 同比增長趨勢分析
  • 絕對量機會分析

第八章全球超重治療市場分析（2019-2023）和預測（2024-2031）：依治療分類

• 簡介/主要發現
• 過去的市場規模分析（2019-2023）：依處理方式
• 目前與未來的市場規模分析與預測（2024-2031）：依處理方式
  • 藥物治療
  • 補充
  • 醫療器材/植入物
• 依處理法進行市場吸引力分析

第9章全球超重治療市場分析（2019-2023）與預測（2024-2031）：依通路

• 簡介/主要發現
• 過去的市場規模分析（2019-2023）：依分銷管道
• 目前和未來的市場規模分析和預測（2024-2031）：依分銷管道
  • 設施銷售
  • 零售銷售
  • 網上銷售
• 依分銷管道劃分的市場吸引力分析

第10章全球超重治療市場分析（2019-2023）與預測（2024-2031）：依地區

• 簡介/主要發現
• 過去的市場規模分析（2019-2023）：依地區
• 依地區劃分的當前和未來市場規模分析和預測（2024-2031）
  • 北美
  • 拉丁美洲
  • 歐洲
  • 東亞
  • 南亞
  • 大洋洲
  • 中東/非洲
• 依地區劃分的市場吸引力分析

第十一章北美超重治療市場分析（2019-2023）與預測（2024-2031）

第十二章拉丁美洲超重治療市場分析（2019-2023）與預測（2024-2031）

第十三章歐洲超重治療市場分析（2019-2023）與預測（2024-2031）

第十四章東亞超重治療市場分析（2019-2023）與預測（2024-2031）

第十五章南亞超重治療市場分析（2019-2023）與預測（2024-2031）

第十六章大洋洲超重治療市場分析（2019-2023）與預測（2024-2031）

第十七章中東和非洲超重治療市場分析（2019-2023）和預測（2024-2031）

第18章市場結構分析

• 依公司層級進行市場分析
• 主要參與者的市場佔有率分析
• 市場存在分析

第 19 章 競爭分析

• 比賽儀表板
• 競爭標桿
• 衝突詳情
  • Novo Nordisk A/S
  • VIVUS LLC
  • AstraZeneca
  • Currax Pharmaceuticals LLC.
  • Spansules Pharmatech Pvt Ltd
  • Atkins Nutritional Inc.
  • Apollo Endosurgery, Inc.
  • Herbalife Nutrition Ltd.
  • SMP Nutra
  • Allurion Technologies
  • ReShape Lifesciences, Inc.
  • Bariatric Solutions GmbH
  • Silimed
  • ENDALIS
  • Districlass Medical
  • Medtronic

第 20 章假設與縮寫

第21章研究方法論

Persistence Market Research presents a comprehensive analysis of the global overweight treatment market, providing insights into its growth drivers, challenges, and emerging trends. This detailed report offers exclusive data and statistics projecting the market's trajectory from 2024 to 2031.

Key Insights:

• Market Size (2024E): US$41.2 Billion
• Projected Market Value (2031F): US$74.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 7.8%

Overweight Treatment Market - Report Scope:

The overweight treatment market addresses the growing concern of obesity and overweight conditions worldwide, offering various therapeutic interventions, lifestyle modifications, and surgical procedures to manage weight and improve overall health. With the rise in sedentary lifestyles, unhealthy dietary habits, and metabolic disorders, obesity has become a global epidemic, driving demand for effective treatment solutions. The market encompasses pharmaceuticals, medical devices, surgical procedures, and lifestyle interventions aimed at weight management and obesity prevention.

Market Growth Drivers:

The increasing prevalence of obesity and overweight conditions, coupled with rising awareness about the health risks associated with excess weight, drives the demand for overweight treatment solutions globally. Lifestyle factors such as poor diet, lack of physical activity, and stress contribute to the obesity epidemic, creating a growing market for weight management therapies and interventions. Additionally, government initiatives, public health campaigns, and reimbursement policies aimed at obesity prevention and treatment further stimulate market growth.

Market Restraints:

Despite the growing awareness and demand for overweight treatment solutions, several challenges hinder market growth. These include limited access to healthcare services in underserved regions, socioeconomic disparities in obesity prevalence, and cultural barriers to adopting healthy lifestyles. Moreover, the stigma associated with obesity and the perception of weight management as a cosmetic issue rather than a medical concern pose challenges for healthcare providers and policymakers in addressing the obesity epidemic effectively.

Market Opportunities:

The evolving landscape of overweight treatment presents opportunities for innovation and collaboration across various sectors, including healthcare, pharmaceuticals, nutrition, and fitness. With advancements in medical technology, there is a growing focus on personalized approaches to weight management, incorporating genetic, metabolic, and behavioral factors into treatment strategies. Furthermore, the integration of digital health solutions, wearable devices, and telemedicine platforms enhances accessibility and engagement in obesity management programs, creating new opportunities for market expansion.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the overweight treatment market?
• How are technological advancements shaping the landscape of obesity management and weight loss interventions?
• What are the key challenges hindering market growth, and how can they be addressed?
• Which regions are expected to witness significant growth in the overweight treatment market?
• Who are the key stakeholders in the market, and what strategies are they adopting to address the obesity epidemic?

Competitive Intelligence and Business Strategy:

Leading players in the overweight treatment market focus on innovation, research, and strategic partnerships to address the complex challenges of obesity management. Pharmaceutical companies invest in the development of novel therapeutics targeting obesity-related metabolic disorders, while medical device manufacturers introduce advanced devices for minimally invasive weight loss procedures. Moreover, healthcare providers collaborate with wellness organizations, nutritionists, and fitness professionals to offer comprehensive weight management programs tailored to individual needs.

Key Companies Profiled:

• Novo Nordisk A/S
• Roche Holding AG
• GlaxoSmithKline plc
• Medtronic plc
• Johnson & Johnson Services, Inc.
• Allergan plc
• Abbott Laboratories
• Pfizer Inc.
• Amgen Inc.
• Merck & Co., Inc.

Overweight Treatment Market Research Segmentation:

Overweight Treatment Market by Treatment:

• Drug Treatment
• Bupropion and Naltrexone
• Orlistat
• Phentermine and Topiramate
• Liraglutide
• Others
• Supplements
• Medical Devices / Implants
• Gastric Balloons
• Gastric Bands
• Stapling Devices

Overweight Treatment Market by Distribution Channel:

• Institutional Sales
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Retail Sales
• Retail Pharmacy
• Drug Stores
• Supermarkets / Hypermarkets
• Health & Beauty Stores
• Online Sales

Overweight Treatment Market by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Technology Roadmap
• 1.5. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption Analysis
• 4.2. Obesity Rate by Country
• 4.3. Obesity Drugs Pipeline Analysis
• 4.4. Obesity Drug Withdrawal Analysis
• 4.5. Obesity Drug / Device Withdrawal, Termination from Clinical Trials
• 4.6. Regulatory Scenario
• 4.7. Key Promotional Strategies by Manufacturers
• 4.8. Porter's Analysis
• 4.9. PESTEL Analysis

5. COVID19 Crisis Analysis

• 5.1. Current COVID19 Statistics and Probable Future Impact
• 5.2. Current GDP Projection and Probable Impact
• 5.3. Current Economic Projection as compared to 2008 Economic analysis
• 5.4. COVID-19 and Impact Analysis
  • 5.4.1. Revenue by Treatment
  • 5.4.2. Revenue by Distribution Channel
  • 5.4.3. Revenue by Country

6. Market Background

• 6.1. Macro-Economic Factors
  • 6.1.1. Global GDP Growth Outlook
  • 6.1.2. Per-Capita Healthcare Expenditure
• 6.2. Forecast Factors - Relevance & Impact
  • 6.2.1. COVID-19 Pandemic
  • 6.2.2. Increasing Prevalence of Obesity
  • 6.2.3. Rise in R&D Investments
  • 6.2.4. Top Overweight Treatment Companies and Their Historical Growth
  • 6.2.5. Rise in Number of Clinical Studies
  • 6.2.6. Increasing Investment in Obesity Research
  • 6.2.7. GDP Growth
  • 6.2.8. Adoption Rate of Overweight Treatment Products
• 6.3. Market Dynamics
  • 6.3.1. Drivers
  • 6.3.2. Restraints
  • 6.3.3. Opportunity Analysis

7. Global Overweight Treatment Market Demand (in Value or Size in US$ MN) Analysis 2019-2023 and Forecast, 2024-2031

• 7.1. Historical Market Value (US$ MN) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ MN) Projections, 2024-2031
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Treatment

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis by Treatment, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Treatment, 2024-2031
  • 8.3.1. Drug Treatment
    • 8.3.1.1. Bupropion and Naltrexone
    • 8.3.1.2. Orlistat
    • 8.3.1.3. Phentermine and Topiramate
    • 8.3.1.4. Liraglutide
    • 8.3.1.5. Others
  • 8.3.2. Supplements
  • 8.3.3. Medical Devices / Implants
    • 8.3.3.1. Gastric Balloons
    • 8.3.3.2. Gastric Bands
    • 8.3.3.3. Stapling Devices
• 8.4. Market Attractiveness Analysis by Treatment

9. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Distribution Channel, 2024-2031
  • 9.3.1. Institutional Sales
    • 9.3.1.1. Hospitals
    • 9.3.1.2. Specialty Clinics
    • 9.3.1.3. Ambulatory Surgical Centers
  • 9.3.2. Retail Sales
    • 9.3.2.1. Retail Pharmacy
    • 9.3.2.2. Drug Stores
    • 9.3.2.3. Supermarkets/ Hypermarkets
    • 9.3.2.4. Health & Beauty Stores
  • 9.3.3. Online Sales
• 9.4. Market Attractiveness Analysis by Distribution Channel

10. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2024-2031
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Treatment
  • 11.3.3. By Distribution Channel
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Treatment
  • 11.4.3. By Distribution Channel
• 11.5. Market Trends
• 11.6. Key Market Participants - Intensity Mapping
• 11.7. Drivers and Restraints - Impact Analysis
• 11.8. Country Level Analysis & Forecast
  • 11.8.1. U.S. Overweight Treatment Market Analysis
    • 11.8.1.1. Introduction
    • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.1.2.1. By Treatment
      • 11.8.1.2.2. By Distribution Channel
  • 11.8.2. Canada Overweight Treatment Market Analysis
    • 11.8.2.1. Introduction
    • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.2.2.1. By Treatment
      • 11.8.2.2.2. By Distribution Channel

12. Latin America Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 12.3.1. By Country
    • 12.3.1.1. Mexico
    • 12.3.1.2. Brazil
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
      • 12.3.1.4.1. By Treatment
      • 12.3.1.4.2. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Treatment
  • 12.4.3. By Distribution Channel
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. Mexico Overweight Treatment Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.1.2.1. By Treatment
      • 12.8.1.2.2. By Distribution Channel
  • 12.8.2. Brazil Overweight Treatment Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.2.2.1. By Treatment
      • 12.8.2.2.2. By Distribution Channel
  • 12.8.3. Argentina Overweight Treatment Market Analysis
    • 12.8.3.1. Introduction
    • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.3.2.1. By Treatment
      • 12.8.3.2.2. By Distribution Channel

13. Europe Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Nordic Countries & Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Treatment
  • 13.3.3. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Treatment
  • 13.4.3. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Germany Overweight Treatment Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Treatment
      • 13.8.1.2.2. By Distribution Channel
  • 13.8.2. Italy Overweight Treatment Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Treatment
      • 13.8.2.2.2. By Distribution Channel
  • 13.8.3. France Overweight Treatment Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.3.2.1. By Treatment
      • 13.8.3.2.2. By Distribution Channel
  • 13.8.4. U.K. Overweight Treatment Market Analysis
    • 13.8.4.1. Introduction
    • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.4.2.1. By Treatment
      • 13.8.4.2.2. By Distribution Channel
  • 13.8.5. Spain Overweight Treatment Market Analysis
    • 13.8.5.1. Introduction
    • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.5.2.1. By Treatment
      • 13.8.5.2.2. By Distribution Channel
  • 13.8.6. BENELUX Overweight Treatment Market Analysis
    • 13.8.6.1. Introduction
    • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.6.2.1. By Treatment
      • 13.8.6.2.2. By Distribution Channel
  • 13.8.7. Nordic Countries & Russia Overweight Treatment Market Analysis
    • 13.8.7.1. Introduction
    • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.7.2.1. By Treatment
      • 13.8.7.2.2. By Distribution Channel

14. East Asia Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
      • 14.3.1.3.1. By Treatment
      • 14.3.1.3.2. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Treatment
  • 14.4.3. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. China Overweight Treatment Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Treatment
      • 14.8.1.2.2. By Distribution Channel
  • 14.8.2. Japan Overweight Treatment Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Treatment
      • 14.8.2.2.2. By Distribution Channel
  • 14.8.3. South Korea Overweight Treatment Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Treatment
      • 14.8.3.2.2. By Distribution Channel

15. South Asia Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Indonesia
    • 15.3.1.3. Malaysia
    • 15.3.1.4. Philippines
    • 15.3.1.5. Thailand
    • 15.3.1.6. Vietnam
    • 15.3.1.7. Rest of South Asia
  • 15.3.2. By Treatment
  • 15.3.3. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Treatment
  • 15.4.3. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. India Overweight Treatment Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Treatment
      • 15.8.1.2.2. By Distribution Channel
  • 15.8.2. Indonesia Overweight Treatment Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Treatment
      • 15.8.2.2.2. By Distribution Channel
  • 15.8.3. Malaysia Overweight Treatment Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Treatment
      • 15.8.3.2.2. By Distribution Channel
  • 15.8.4. Philippines Overweight Treatment Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Treatment
      • 15.8.4.2.2. By Distribution Channel
  • 15.8.5. Thailand Overweight Treatment Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Treatment
      • 15.8.5.2.2. By Distribution Channel
  • 15.8.6. Vietnam Overweight Treatment Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Treatment
      • 15.8.6.2.2. By Distribution Channel

16. Oceania Overweight Treatment Market 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Treatment
  • 16.3.3. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Treatment
  • 16.4.3. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Australia Overweight Treatment Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Treatment
      • 16.8.1.2.2. By Distribution Channel
  • 16.8.2. New Zealand Overweight Treatment Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Treatment
      • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Israel
    • 17.3.1.3. Turkey
    • 17.3.1.4. South Africa & North Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Treatment
  • 17.3.3. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Treatment
  • 17.4.3. By Distribution Channel
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. GCC Countries Overweight Treatment Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Treatment
      • 17.8.1.2.2. By Distribution Channel
  • 17.8.2. Israel Overweight Treatment Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Treatment
      • 17.8.2.2.2. By Distribution Channel
  • 17.8.3. Turkey Overweight Treatment Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Treatment
      • 17.8.3.2.2. By Distribution Channel
  • 17.8.4. South Africa & North Africa Overweight Treatment Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Treatment
      • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Share Analysis of Top Players
• 18.3. Market Presence Analysis
  • 18.3.1. Regional footprint of Players
  • 18.3.2. Channel Foot Print by Players

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Benchmarking
• 19.3. Competition Deep Dive
  • 19.3.1. Novo Nordisk A/S
    • 19.3.1.1. Overview
    • 19.3.1.2. Product Portfolio
    • 19.3.1.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.1.4. Sales Footprint
    • 19.3.1.5. Strategy Overview
    • 19.3.1.6. SWOT Analysis
  • 19.3.2. VIVUS LLC
    • 19.3.2.1. Overview
    • 19.3.2.2. Product Portfolio
    • 19.3.2.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.2.4. Sales Footprint
    • 19.3.2.5. Strategy Overview
    • 19.3.2.6. SWOT Analysis
  • 19.3.3. AstraZeneca
    • 19.3.3.1. Overview
    • 19.3.3.2. Product Portfolio
    • 19.3.3.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.3.4. Sales Footprint
    • 19.3.3.5. Strategy Overview
    • 19.3.3.6. SWOT Analysis
  • 19.3.4. Currax Pharmaceuticals LLC.
    • 19.3.4.1. Overview
    • 19.3.4.2. Product Portfolio
    • 19.3.4.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.4.4. Sales Footprint
    • 19.3.4.5. Strategy Overview
    • 19.3.4.6. SWOT Analysis
  • 19.3.5. Spansules Pharmatech Pvt Ltd
    • 19.3.5.1. Overview
    • 19.3.5.2. Product Portfolio
    • 19.3.5.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.5.4. Sales Footprint
    • 19.3.5.5. Strategy Overview
    • 19.3.5.6. SWOT Analysis
  • 19.3.6. Atkins Nutritional Inc.
    • 19.3.6.1. Overview
    • 19.3.6.2. Product Portfolio
    • 19.3.6.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.6.4. Sales Footprint
    • 19.3.6.5. Strategy Overview
    • 19.3.6.6. SWOT Analysis
  • 19.3.7. Apollo Endosurgery, Inc.
    • 19.3.7.1. Overview
    • 19.3.7.2. Product Portfolio
    • 19.3.7.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.7.4. Sales Footprint
    • 19.3.7.5. Strategy Overview
    • 19.3.7.6. SWOT Analysis
  • 19.3.8. Herbalife Nutrition Ltd.
    • 19.3.8.1. Overview
    • 19.3.8.2. Product Portfolio
    • 19.3.8.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.8.4. Sales Footprint
    • 19.3.8.5. Strategy Overview
    • 19.3.8.6. SWOT Analysis
  • 19.3.9. SMP Nutra
    • 19.3.9.1. Overview
    • 19.3.9.2. Product Portfolio
    • 19.3.9.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.9.4. Sales Footprint
    • 19.3.9.5. Strategy Overview
    • 19.3.9.6. SWOT Analysis
  • 19.3.10. Allurion Technologies
    • 19.3.10.1. Overview
    • 19.3.10.2. Product Portfolio
    • 19.3.10.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.10.4. Sales Footprint
    • 19.3.10.5. Strategy Overview
    • 19.3.10.6. SWOT Analysis
  • 19.3.11. ReShape Lifesciences, Inc.
    • 19.3.11.1. Overview
    • 19.3.11.2. Product Portfolio
    • 19.3.11.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.11.4. Sales Footprint
    • 19.3.11.5. Strategy Overview
    • 19.3.11.6. SWOT Analysis
  • 19.3.12. Bariatric Solutions GmbH
    • 19.3.12.1. Overview
    • 19.3.12.2. Product Portfolio
    • 19.3.12.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.12.4. Sales Footprint
    • 19.3.12.5. Strategy Overview
    • 19.3.12.6. SWOT Analysis
  • 19.3.13. Silimed
    • 19.3.13.1. Overview
    • 19.3.13.2. Product Portfolio
    • 19.3.13.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.13.4. Sales Footprint
    • 19.3.13.5. Strategy Overview
    • 19.3.13.6. SWOT Analysis
  • 19.3.14. ENDALIS
    • 19.3.14.1. Overview
    • 19.3.14.2. Product Portfolio
    • 19.3.14.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.14.4. Sales Footprint
    • 19.3.14.5. Strategy Overview
    • 19.3.14.6. SWOT Analysis
  • 19.3.15. Districlass Medical
    • 19.3.15.1. Overview
    • 19.3.15.2. Product Portfolio
    • 19.3.15.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.15.4. Sales Footprint
    • 19.3.15.5. Strategy Overview
    • 19.3.15.6. SWOT Analysis
  • 19.3.16. Medtronic
    • 19.3.16.1. Overview
    • 19.3.16.2. Product Portfolio
    • 19.3.16.3. Key Financials by Market Segments (Product/Channel/Region)
    • 19.3.16.4. Sales Footprint
    • 19.3.16.5. Strategy Overview
    • 19.3.16.6. SWOT Analysis

20. Assumptions and Acronyms Used

21. Research Methodology